These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 36368608)

  • 21. Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Moxifloxacin Hydrochloride.
    Charoo NA; Abdallah DB; Parveen T; Abrahamsson B; Cristofoletti R; Groot DW; Langguth P; Parr A; Polli JE; Mehta M; Shah VP; Tajiri T; Dressman J
    J Pharm Sci; 2020 Sep; 109(9):2654-2675. PubMed ID: 32534881
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predicting Pharmacokinetics of Multisource Acyclovir Oral Products Through Physiologically Based Biopharmaceutics Modeling.
    García MA; Bolger MB; Suarez-Sharp S; Langguth P
    J Pharm Sci; 2022 Jan; 111(1):262-273. PubMed ID: 34678271
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In Vitro Biopredictive Methods: A Workshop Summary Report.
    Pepin XJH; Dressman J; Parrott N; Delvadia P; Mitra A; Zhang X; Babiskin A; Kolhatkar V; Seo P; Taylor LS; Sjögren E; Butler JM; Kostewicz E; Tannergren C; Koziolek M; Kesisoglou F; Dallmann A; Zhao Y; Suarez-Sharp S
    J Pharm Sci; 2021 Feb; 110(2):567-583. PubMed ID: 32956678
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prediction of pH-Dependent Drug-Drug Interactions for Basic Drugs Using Physiologically Based Biopharmaceutics Modeling: Industry Case Studies.
    Mitra A; Parrott N; Miller N; Lloyd R; Tistaert C; Heimbach T; Ji Y; Kesisoglou F
    J Pharm Sci; 2020 Mar; 109(3):1380-1394. PubMed ID: 31778721
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Physiologically Based Biopharmaceutics Model of Vildagliptin Modified Release (MR) Tablets to Predict In Vivo Performance and Establish Clinically Relevant Dissolution Specifications.
    Madny MA; Deshpande P; Tumuluri V; Borde P; Sangana R
    AAPS PharmSciTech; 2022 Apr; 23(4):108. PubMed ID: 35386066
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BCS-based biowaivers: Extension to paediatrics.
    Martir J; Flanagan T; Mann J; Fotaki N
    Eur J Pharm Sci; 2020 Dec; 155():105549. PubMed ID: 32941998
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of preclinical dog studies and absorption modeling to facilitate late stage formulation bridging for a BCS II drug candidate.
    Kesisoglou F
    AAPS PharmSciTech; 2014 Feb; 15(1):20-28. PubMed ID: 24022346
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Application of physiologically based biopharmaceutics modeling to understand the impact of dissolution differences on in vivo performance of immediate release products: The case of bisoprolol.
    Macwan JS; Fraczkiewicz G; Bertolino M; Krüger P; Peters SA
    CPT Pharmacometrics Syst Pharmacol; 2021 Jun; 10(6):622-632. PubMed ID: 34080804
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Physiologically Based Biopharmaceutics Modeling of Regional and Colon Absorption in Dogs.
    Eckernäs E; Tannergren C
    Mol Pharm; 2021 Apr; 18(4):1699-1710. PubMed ID: 33720733
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparative analysis of biopharmaceutics classification system and biopharmaceutics drug disposition classification system: a cross-sectional survey with 500 bioequivalence studies.
    Cristofoletti R; Chiann C; Dressman JB; Storpirtis S
    J Pharm Sci; 2013 Sep; 102(9):3136-44. PubMed ID: 23580377
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current status and future opportunities for incorporation of dissolution data in PBPK modeling for pharmaceutical development and regulatory applications: OrBiTo consortium commentary.
    Jamei M; Abrahamsson B; Brown J; Bevernage J; Bolger MB; Heimbach T; Karlsson E; Kotzagiorgis E; Lindahl A; McAllister M; Mullin JM; Pepin X; Tistaert C; Turner DB; Kesisoglou F
    Eur J Pharm Biopharm; 2020 Oct; 155():55-68. PubMed ID: 32781025
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of a Clinically Relevant Dissolution Method for Metaxalone Immediate Release Formulations Based on an IVIVC Model.
    Vuletić L; Khan MZI; Špoljarić D; Radić M; Cetina-Čižmek B; Filipović-Grčić J
    Pharm Res; 2018 Jun; 35(8):163. PubMed ID: 29934663
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of Excipient Risk in BCS Class I and III Biowaivers.
    Metry M; Polli JE
    AAPS J; 2022 Jan; 24(1):20. PubMed ID: 34988701
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral biopharmaceutics tools - time for a new initiative - an introduction to the IMI project OrBiTo.
    Lennernäs H; Aarons L; Augustijns P; Beato S; Bolger M; Box K; Brewster M; Butler J; Dressman J; Holm R; Julia Frank K; Kendall R; Langguth P; Sydor J; Lindahl A; McAllister M; Muenster U; Müllertz A; Ojala K; Pepin X; Reppas C; Rostami-Hodjegan A; Verwei M; Weitschies W; Wilson C; Karlsson C; Abrahamsson B
    Eur J Pharm Sci; 2014 Jun; 57():292-9. PubMed ID: 24189462
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Biopharmaceutics Classification System: subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC.
    Tsume Y; Mudie DM; Langguth P; Amidon GE; Amidon GL
    Eur J Pharm Sci; 2014 Jun; 57():152-63. PubMed ID: 24486482
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current State and Future Expectations of Translational Modeling Strategies to Support Drug Product Development, Manufacturing Changes and Controls: A Workshop Summary Report.
    Pepin XJH; Parrott N; Dressman J; Delvadia P; Mitra A; Zhang X; Babiskin A; Kolhatkar V; Suarez-Sharp S
    J Pharm Sci; 2021 Feb; 110(2):555-566. PubMed ID: 32380182
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PBPK Absorption Modeling of Food Effect and Bioequivalence in Fed State for Two Formulations with Crystalline and Amorphous Forms of BCS 2 Class Drug in Generic Drug Development.
    Rebeka J; Jerneja O; Igor L; Boštjan P; Aleksander B; Simon Ž; Albin K
    AAPS PharmSciTech; 2019 Jan; 20(2):59. PubMed ID: 30623248
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluating the bioequivalence of metronidazole tablets and analyzing the effect of
    Zhang S; Fang M; Zhang Q; Li X; Zhang T
    Drug Dev Ind Pharm; 2019 Oct; 45(10):1646-1653. PubMed ID: 31342807
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Using Tiny-TIM Dissolution and In Silico Simulation to Accelerate Oral Product Development of a BCS Class II Compound.
    Luo L; Thakral NK; Schwabe R; Li L; Chen S
    AAPS PharmSciTech; 2022 Jul; 23(6):185. PubMed ID: 35778639
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biowaiver monographs for immediate release solid oral dosage forms: piroxicam.
    Shohin IE; Kulinich JI; Ramenskaya GV; Abrahamsson B; Kopp S; Langguth P; Polli JE; Shah VP; Groot DW; Barends DM; Dressman JB
    J Pharm Sci; 2014 Feb; 103(2):367-77. PubMed ID: 24301077
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.